New study tracks Real-World use of hair loss drug litfulo
NCT ID NCT06279221
First seen Mar 07, 2026 · Last updated May 21, 2026 · Updated 9 times
Summary
This study follows 487 people with alopecia areata who are taking Litfulo capsules for the first time. Researchers want to confirm the drug's safety and how well it works in everyday use, not just in controlled trials. They will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning 80% or more scalp hair coverage).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.